A user shared progress pictures showing significant hair improvement after using a topical 0.3% finasteride/6% minoxidil solution from January to June 2024. They experienced initial shedding but saw progressive improvement with daily evening application.
A user's experience with hair loss treatments, including finasteride, minoxidil, dutasteride, biotin and micro needling; the user is concerned about their hairline after switching to dutasteride and oral minoxidil. Responses suggest that this could be just a shed and offers advice on how to possibly address it.
The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.
The user has been using finasteride, minoxidil, and other treatments for nearly a year without progress in hair regrowth, feeling frustrated and depressed. Suggestions include trying dutasteride, considering a scalp biopsy, and acknowledging that stopping hair loss might be the only achievable outcome.
The conversation discusses a hair loss treatment regimen including oral dutasteride, oral minoxidil, tadalafil, and the recent addition of RU58841. The user shares experiences with these treatments, noting significant hair regrowth and stabilization, and discusses the cost and preparation of RU58841.
The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
The user reported high testosterone and estradiol levels within range, but unexpectedly high DHT levels after using finasteride and dutasteride for hair loss. Another person suggested the dutasteride might be fake or a bad batch and recommended using the branded Avodart.
The conversation discusses the potential use of verteporfin for hair loss treatment, with one user mentioning their surgeon's interest in trying it and another noting its research status and clinical use as a YAP inhibitor. Some users debate the market size, availability of generics, and the optimism in the hair loss community regarding new treatments.